NCT01306032

ABT-888 (veliparib)With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian TubeCancer, Triple-NegativeBreast Cancer, and Low-Grade Non-Hodgkin's Lymphoma

Study identifier: NCT01306032
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)

Eligibility:

Triple-negative breast cancer which has progressed following at least one line of therapy. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral CT scan.

Type of study:

Randomized, Phase II trial for patients with triple-negative breast cancer 

Treatment:

Patients will be randomized to receive either oral cyclophosphamide alone or oral cyclophosphamide in combination with ABT-888.

Study sites:

For all study sites, please contact:

Deborah E. Allen, R.N. (301) 402-5640 allendeb@mail.nih.gov

California

University of California, Davis     
Davis, California, 95616

Florida

H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida,  33612

Illinois

University of Chicago     
Chicago, Illinois, 60637

Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pike   
Bethesda, Maryland, United States, 20892

Minnesota

Mayo Clinic, Rochester  
Rochester, Minnesota, 55905

Nebraska

University of Nebraska Med. Ctr. Eppley Cancer Ctr.
Omaha, Nebraska, 68198-5950

New York

Montefiore Medical Center
Bronx, New York, 10467

Memorial Sloan Kettering Cancer Center
New York, New York, 10021

Ohio

Ohio State University      
Columbus, Ohio, United States, 43210-1240

Texas

MD Anderson Cancer Center
Houston, Texas, 77030-4096

Ontario

Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9 

 

Page updated 03/21/11  

Web design by Rareheron Web Design